By DaXem GmbH | virexbuster.de | Published: 13 July 2026
The conversation about antimicrobial resistance (AMR) usually centres on antibiotics: overuse, misuse, and the shrinking pipeline of effective drugs. That framing is correct but incomplete. In July 2026, surgeons warned that resistance is emerging as a major threat to surgical care, where a single post-operative infection with a resistant organism can turn a routine procedure into a life-threatening event. What is often left out of that warning is how these organisms reach the patient in the first place — and surfaces are a large part of the answer.
Resistant Pathogens Live on Surfaces, Not Just in Patients
Two recent patterns make the point clearly:
- Candida auris has been designated by the US CDC as an urgent antimicrobial threat — the first fungal pathogen to receive that label. It spreads readily in hospitals and long-term care facilities precisely because it survives on skin and on hard surfaces, resisting many routine cleaning agents.
- NDM-producing Pseudomonas aeruginosa, a highly drug-resistant strain, was traced in one Southern California hospital to a single contaminated ICU sink. Eight patients tested positive for the same strain over eighteen months before the plumbing reservoir was identified.
Neither case was primarily about prescribing. Both were about a resistant organism finding a surface reservoir and using it to move from one patient to the next. When the pathogen is resistant to the drugs that would normally treat it, stopping that surface-to-patient transfer becomes disproportionately important.
Why Disinfection Alone Leaves a Gap
Terminal cleaning and routine disinfection are the backbone of infection prevention, and nothing here replaces them. But they share one structural limitation: they act only at the instant they are applied. The moment a disinfected surface dries, it is exposed again — to hands, gloves, equipment, droplets, and airborne organisms that resettle continuously. In a busy clinical environment, a high-touch surface can be recontaminated within minutes of being cleaned.
For an ordinary, treatable organism this recontamination window is a manageable risk. For a resistant organism that survives on surfaces and has few remaining treatment options, the same window is far more dangerous. This is the gap between cleaning cycles — and it is exactly where a residual approach adds value.
What a Supplemental Residual Antimicrobial Coating Does
VireXbuster Spray is an antimicrobial surface coating. It is a hybrid formulation with a very wide spectrum of activity against viruses, bacteria, fungi, mould, and mildew. Applied to a surface, it forms a durable protective layer that remains active continuously, working to reduce microbial survival on the surface itself between the cleaning and disinfection events a facility already performs.
An important distinction: VireXbuster is not classified as a disinfectant. In the United States, the EPA defines this category as a Supplemental Residual Antimicrobial Product — supplemental because it works alongside standard disinfection, and residual because it keeps working after the disinfectant has dried. It does not replace cleaning protocols. It changes what happens to the surface in the hours between them, which is where resistant organisms exploit the recontamination window.
VireXbuster is:
- BAuA approved for use in Germany
- Fraunhofer Institut tested
- QualityLabs certified as antimicrobial
- Dermatest certified “Excellent” — dermatologically safe
Where a Residual Layer Matters Most
- Healthcare facilities — high-touch surfaces in ICUs, surgical wards, patient rooms, and sanitary areas where resistant organisms are most likely to establish a reservoir
- Long-term care — settings where Candida auris transmission is well documented and where residents have prolonged surface contact
- Public sector and transit — high-traffic shared surfaces with intensive touch loads between cleaning rounds
- Hospitality — guest rooms and shared facilities where continuous protection supports a visibly higher hygiene standard
For manufacturers, the same chemistry is available as VireXbuster 4Bulk, an additive that builds antimicrobial activity directly into polymers and plastics — including materials used for polymer floors and moulded components — and as VireXbuster Wall for antimicrobial protection of walls and ceilings.
Frequently Asked Questions
Does an antimicrobial coating replace cleaning and disinfection?
No. VireXbuster is a supplemental residual antimicrobial, not a disinfectant. It works alongside a facility’s existing cleaning and disinfection protocols, providing continuous protection on the surface between those events. It does not replace them.
Can an antimicrobial coating help against antibiotic-resistant organisms?
VireXbuster acts on the surface to reduce the microbial bioburden that pathogens rely on to survive and spread between cleaning cycles. Because resistance to antibiotics does not change how an organism is affected by a surface coating, reducing surface contamination is a useful complementary layer, especially where resistant organisms are known to persist on surfaces.
How long does the protection last?
VireXbuster forms a durable coating designed to remain active between routine cleaning cycles. Longevity depends on the surface, traffic, and cleaning regime; contact DaXem for facility-specific technical data.
Is it safe for occupied clinical environments?
Yes. VireXbuster is Dermatest certified “Excellent” for dermatological safety and BAuA approved for use in Germany.
To review technical data sheets or discuss a facility assessment, visit virexbuster.de/contact-us or browse the full product range at virexbuster.de/shop.
